Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database: A Disproportionality Analysis

By Shamloo Behrooz K.  

Drug Safety, Vol. 35, Iss. 6, 2012-06 ,pp. : 507-518

Adis International

Access to resources Recommend Favorite

Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database

By Motola Domenico  

Drug Safety, Vol. 35, Iss. 4, 2012-04 ,pp. : 315-323

Adis International

Access to resources Recommend Favorite

`Extreme Duplication' in the US FDA Adverse Events Reporting System Database

By Hauben Manfred   Reich Lester   DeMicco James   Kim Katherine  

Drug Safety, Vol. 30, Iss. 6, 2007-01 ,pp. : 551-554

Adis International

Access to resources Recommend Favorite

Comparison of Sensitivity and Timing of Early Signal Detection of Four Frequently Used Signal Detection Methods: An Empirical Study Based on the US FDA Adverse Event Reporting System Database

By Chen Yan  

Pharmaceutical Medicine, Vol. 22, Iss. 6, 2008-01 ,pp. : 359-365

Adis International

Access to resources Recommend Favorite

Drug-versus-Drug Adverse Event Rate Comparisons: A Pilot Study Based on Data from the US FDA Adverse Event Reporting System

By Hochberg Alan M.   Pearson Ronald K.   O'Hara Donald J.   Reisinger Stephanie J.  

Drug Safety, Vol. 32, Iss. 2, 2009-01 ,pp. : 137-146

Adis International

Access to resources Recommend Favorite